Core Viewpoint - The review of the long-acting follicle-stimulating hormone has been suspended due to reaching the review deadline, and the company is currently awaiting supplementary comments [1] Company Summary - 双鹭药业 (Shuanglu Pharmaceutical) has communicated with investors regarding the status of its long-acting follicle-stimulating hormone review process [1]

Core Viewpoint - As of September 30, 2025, the total number of shareholders for Shuanglu Pharmaceutical is reported to be 54,779 [2] Company Summary - Shuanglu Pharmaceutical responded to investor inquiries on November 3, indicating the total number of shareholders [2]

Group 1 - The company Shuanglu Pharmaceutical announced on November 3 that its adenosylmethionine has been successfully awarded a bid [2] - The planned bidding regions include Shandong, Hubei, Tianjin, Shanxi, and Ningxia [2]

Core Viewpoint - Shuanglu Pharmaceutical has successfully launched its nitroglycerin spray, and the market promotion is progressing in an orderly manner [2] Company Summary - Shuanglu Pharmaceutical's nitroglycerin spray has been officially launched [2] - The company is actively promoting the product in the market [2]

Core Viewpoint - The company is preparing to submit the NDA for its GLP-1 long-acting product after addressing feedback and completing necessary documentation [2] Group 1 - Investors inquired about the delay in the NDA submission for the GLP-1 long-acting product, which has been pending for nearly a year [2] - The company confirmed that it is currently organizing and refining the required materials for the NDA submission and is conducting drug inspections [2] - The company will provide updates on the progress of the NDA submission as new developments arise [2]

Group 1 - The company Shuanglu Pharmaceutical has won the bid for adenosylmethionine in the 11th batch of centralized procurement [2] - The winning price for the product is set at 9.26 per unit [2] - The regions where the product has been awarded include Shandong, Hubei, Tianjin, Shanxi, and Ningxia [2]

Group 1 - The company holds a 0.34% stake in XuanZhu Biotechnology Co., Ltd., amounting to 1.7808 million shares [2] - The investment in XuanZhu Biotechnology was made through a capital increase, with a total investment of 20.6346 million [2] - The average cost per share for the company is 11.59 yuan [2]

Group 1 - The core issue is the suspension of the review for the long-acting follicle-stimulating hormone by the company due to reaching the review deadline and currently awaiting supplementary comments [2]

Core Viewpoint - The company is preparing to submit documentation for its long-acting GLP-1 product, indicating progress in its development pipeline [1] Group 1 - The company announced on November 3 that it is organizing materials for submission regarding its GLP-1 long-acting product [1]

Core Viewpoint - The company has successfully launched its nitroglycerin spray and is currently advancing its market promotion efforts [1] Company Summary - The nitroglycerin spray has officially been released to the market [1] - Market promotion for the product is progressing in an orderly manner [1]